Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
Rheumatology (Oxford). 2024 May 3;63(6):1656-1663. doi: 10.1093/rheumatology/kead461.
Adult-onset Still's disease (AOSD) is a rare condition characterized by fevers, rash, and arthralgia/arthritis; most doctors treating AOSD in the Netherlands treat <5 patients per year. Currently, there is no internationally accepted treatment guideline for AOSD. The objectives of this study were to conduct a Delphi panel aimed at reaching consensus about diagnostic and treatment strategies for patients with AOSD and to use the outcomes as a basis for a treatment algorithm.
The Delphi panel brought together 18 AOSD experts: rheumatologists, internists and paediatricians. The Delphi process consisted of three rounds. In the first two rounds, online lists of questions and statements were completed. In the third round, final statements were discussed during a virtual meeting and a final vote took place. Consensus threshold was set at 80%. Two targeted literature searches were performed identifying the level of evidence of the consensus-based statements.
Consensus was reached on 29 statements, including statements related to diagnosis and diagnostic tests, definition of response and remission, the therapy, the use of methotrexate and tapering of treatment. The panel consented on reduction of the use of glucocorticoids to avoid side effects, and preferred the use of biologics over conventional treatment. The role of IL-1 and IL-6 blocking agents was considered important in the treatment of AOSD.
In this Delphi panel, a high level of consensus was achieved on recommendations for diagnosis and therapy of AOSD that can serve as a basis for a treatment guideline.
成人Still 病(AOSD)是一种罕见的疾病,其特征为发热、皮疹和关节炎/关节痛;荷兰大多数治疗 AOSD 的医生每年治疗的患者少于 5 例。目前,尚无国际公认的 AOSD 治疗指南。本研究的目的是进行一项 Delphi 小组研究,旨在就 AOSD 患者的诊断和治疗策略达成共识,并将结果用作治疗算法的基础。
Delphi 小组汇集了 18 名 AOSD 专家:风湿病学家、内科医生和儿科医生。Delphi 流程包括三个回合。在前两轮中,在线完成了问题和陈述清单。在第三轮中,在虚拟会议上讨论了最终陈述,并进行了最终投票。共识阈值设定为 80%。进行了两次有针对性的文献检索,以确定基于共识的陈述的证据水平。
就 29 项声明达成了共识,包括与诊断和诊断测试、反应和缓解的定义、治疗、甲氨蝶呤的使用和治疗的减量相关的声明。专家组同意减少使用糖皮质激素以避免副作用,并倾向于使用生物制剂而不是常规治疗。IL-1 和 IL-6 阻断剂在 AOSD 的治疗中被认为很重要。
在这项 Delphi 小组研究中,就 AOSD 的诊断和治疗建议达成了高度共识,可为治疗指南提供依据。